Lercanidipinhydrochlorid Rivopharm (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium entry, which leads to relaxation of arterial walls, vasodilation, and a decrease in peripheral vascular resistance that lowers systemic blood pressure.

The appropriate dose of lercanidipine is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s specific instructions.

Safety of lercanidipine in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may be associated with a lower incidence of peripheral edema, while amlodipine is more widely studied and available in fixed‑dose combinations.

Lercanidipinhydrochlorid Rivopharm should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Lercanidipine is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the same time each day, and may be taken with or without food as directed by the prescriber.

Serious adverse events, although rare, include severe hypotension, angioedema (swelling of the face, lips, tongue, or throat), hepatic dysfunction, and significant cardiac arrhythmias. Patients should seek immediate medical attention if they experience any of these symptoms.

Lercanidipine should be avoided in individuals with known hypersensitivity to the drug or any component of the formulation, in patients with severe hepatic impairment, and in those experiencing uncontrolled hypotension. Clinicians should also assess suitability in patients with certain cardiac conditions.